Is co-overexpression of HER2/HER3 a predictor of impaired survival in breast cancer patients?
HER2/HER3 co-overexpression is significantly associated with impaired OS from diagnosis of metastatic disease in patients with HER2-positive metastatic breast cancer. Co-inhibition of HER2 and HER3 or the inhibition of HER2/HER3 hetero-dimerization may improve clinical outcome in this subgroup.
Essential supplies such as iron supplements are in short supply and emergency obstetric care services are nonexistent in the public health system in our study area. The NRHM needs to address the ground realities to make motherhood safe.